Tigecycline MIC Testing by Broth Dilution Requires Use of Fresh Medium or Addition of the Biocatalytic Oxygen-Reducing Reagent Oxyrase To Standardize the Test Method
Open Access
- 1 September 2005
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (9), 3903-3909
- https://doi.org/10.1128/aac.49.9.3903-3909.2005
Abstract
Tigecycline is a broad-spectrum glycylcycline antibiotic with activity against not only susceptible gram-positive and gram-negative pathogens but also strains that are resistant to many other antibiotics. In the process of determining quality control (QC) limits for the American Type Culture Collection reference strains for tigecycline, a number of inconsistencies in MICs were encountered which appeared to be related to the age of the Mueller-Hinton broth (MHB) medium used in the MIC testing. The objective of this study was to determine the cause of the discrepant MIC results between fresh and aged MHB. The MICs of tigecycline were determined in MHB that was either prepared fresh (3 log10 difference in viable growth when tigecycline was tested in fresh or Oxyrase-supplemented MHB compared to aged MHB. High-pressure liquid chromatography analysis revealed the accumulation of an early peak (oxidative by-product of tigecycline) to be 3.5% in fresh media and 25.1% in aged media after 24 h and that addition of Oxyrase prevented the accumulation of this oxidized by-product. These results suggested that the activity of tigecycline was affected by the amount of dissolved oxygen in the media. The use of fresh MHB or supplementation with Oxyrase resulted in a more standardized test method for performing MIC tests with tigecycline.Keywords
This publication has 14 references indexed in Scilit:
- In Vitro Activities of Tigecycline against the Bacteroides fragilis GroupAntimicrobial Agents and Chemotherapy, 2004
- Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNAJournal of Antimicrobial Chemotherapy, 2004
- Activities of the Glycylcycline Tigecycline (GAR-936) against 1,924 Recent European Clinical Bacterial IsolatesAntimicrobial Agents and Chemotherapy, 2003
- Comparison of the In Vitro Activity of the Glycylcycline Tigecycline (Formerly GAR-936) with Those of Tetracycline, Minocycline, and Doxycycline against Isolates of Nontuberculous MycobacteriaAntimicrobial Agents and Chemotherapy, 2002
- Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureusInternational Journal of Antimicrobial Agents, 2002
- In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-IntermediateStaphylococcus aureusand Other Resistant Gram-Positive PathogensAntimicrobial Agents and Chemotherapy, 2002
- Susceptibilities of Mycoplasma hominis, M. pneumoniae , and Ureaplasma urealyticum to GAR-936, Dalfopristin, Dirithromycin, Evernimicin, Gatifloxacin, Linezolid, Moxifloxacin, Quinupristin-Dalfopristin, and Telithromycin Compared to Their Susceptibilities to Reference Macrolides, Tetracyclines, and QuinolonesAntimicrobial Agents and Chemotherapy, 2001
- In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatisInternational Journal of Antimicrobial Agents, 2000
- In-vitro susceptibility of anaerobic bacteria to gar-936, a new glycylcyclineClinical Microbiology & Infection, 2000
- Stability of minocycline, doxycycline, and tetracycline stored in agar plates and microdilution traysCurrent Microbiology, 1978